Stem Cell Technologies and Applications Market Report 2016-2026

LONDON, December 8, 2015 /PRNewswire/ --

Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking

Stem cells - discover revenue prospects and developments for cancer treatment, cardiovascular therapy, CNS uses, other therapies and non-therapeutic applications
What does the future hold for stem cells? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.

Visiongain's new investigation gives you revenue forecasts to 2026 for the world stem cells market, submarkets and leading products. Avoid missing out. There see what is happening for those cell-based technologies and their uses, discovering the most lucrative applications.

See what gains are possible. Please read on, then, to explore that industry and discover what its future market could be worth.

Forecasts and other analyses showing opportunities in those cellular technologies
Besides revenue forecasting to 2026, our analyses show recent results, growth rates and market shares. There you find original analysis. Our work also explains research and development. You gain 68 tables, 41 charts and our interviews with five authorities.

Now make your searching for data on stem cells easier. Also save time and benefit your insight and authority. Our study's purpose is to benefit your research, analysis and decisions, helping you see where developments and money lie, staying ahead in knowledge.

The following sections show how visiongain's new investigation helps your work.

Prospects for the overall world market and segments - what is possible?
What are the secrets of that industry's progress? Along with our prediction of the overall world market value for stem cells, our study shows you individual revenue forecasting of five submarkets to 2026 at world level, with discussions:
• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Which segment will achieve highest sales? Which has fastest predicted growth? See how and why those commercial uses in healthcare will develop, prosper and gain in importance.

For developers, producers and sellers, assess how those tools, systems and applications earn money. Also gauge their potential success from 2016, finding the most lucrative applications.

Products - discover sales forecasting for leading therapies
Our study also shows you individual revenue predictions to 2026 for six top brands:
• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).

In our analyses you discover prospects for established and emerging technology and medicines. That market will expand through the approval and launch of many products from 2016.

Our study explains what the future holds, discussing issues to help your work.

Developments, challenges and opportunities affecting researchers, producers and users
Our investigation lets you assess trends, R&D and outlooks for stem cell technology. There you find discussions of forces, progress and potential:
• Developments in the US, Japan, Europe, South Korea, China, India and Israel - regulations, progress, potentials, expertise, regional prominence and outlooks
• Activities of Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost and other organisations, private and public - explore prominent and rising competitors
• Approvals of therapies and other products to expand and advance that industry
• Treatments for orphan diseases and difficult-to-cure disorders
• Regenerative medicine and uses in diabetes, liver repair, Crohn's disease, rheumatoid arthritis, eye disorders and other therapeutic applications.

Out study discusses other influences on that field, including these:
• Haematopoietic stem cell transplantation (HSCT)
• Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
• Uses for umbilical cord blood and related technologies, including cellular and blood banking
• Agents for osteogenesis and treating autoimmune conditions
• Applications in cell-based assays, diagnostics and drug development.

There you explore political, economic, social and technological questions, assessing advances and prospects. You also gain in regulatory insight. You investigate what helps and restrains stem cell developers, producers and marketers, seeing what they can achieve.

Discover in our report what the past, present and future hold for those cellular technologies.

Stem cells - what revenue could that overall world market earn in 2019?
From 2016 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for stem cells will reach $15.8bn in 2019, achieving double-digit revenue growth from 2015 to 2026.

Our report's author said: "Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood bank services and cell-based assays will stimulate this market over the next ten years."

Prospects for those medical products, systems and tools are great. From 2015 there will arise many opportunities. Our work explains what is possible, helping you stay ahead in knowledge and influence.

Stem Cell Technologies and Applications Market Report 2016-2026  shows data and analysis you find nowhere else
In particular you gain these analyses to help your research, plans, decisions and presentations:
• Overall world revenue to 2026 - see the results and sales potential of that industry
• Five submarkets' revenues to 2026 - investigate segments at world level, finding the most promising and lucrative applications
• Six product revenues to 2026 - discover sales predictions for top medical agents, seeing how they can succeed, including what helps and limits their performance
• R&D on stem cells - investigate progress, finding technological, clinical and commercial outlooks, exploring expected products
• Activities of established, rising and emerging companies - hear about firms' capabilities, portfolios, advances and prospects
• Interviews with five organisations - explore views to benefit your work, helping you assess that sector, its participants and potential
• Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete, gain advantages and succeed.

You also receive our interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston's Children's Hospital.

Potential for stem cells - discover now what is possible for those organisations
With our study you receive business intelligence found only in our work, discovering where money, progress and opportunities lie. That way you can benefit your influence and reputation for insight, staying ahead in knowledge. Gain information you find nowhere else.

With our new investigation you are less likely to miss opportunity or fall behind. There you explore trends, R&D and sales predications. Stay ahead by getting our report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1541/Stem-Cell-Technologies-and-Applications-Market-Report-2016-2026

Companies Listed

3-D Matrix
Aastrom Biosciences
Adistem
Advanced Cell Technology
Alder Biopharmaceuticals
Alkems
AllCells
Allergan
AlloSource
American Academy of Neurology
American Academy of Pediatrics (AAP)
American Neurological Associates Annual Meeting
American Society of Blood and Marrow Transplantation.
Americas Committee for Treatment and Research in Multiple Sclerosis
Americord
Amgen
Angiocrine Bioscience
Anterogen
Antria
Apceth
Arteriocyte
Associated Press
Asterias Biotherapeutics
Athersys
Auriga Ventures
Axiogenesis
Baxter Healthcare
BaYi Brain Hospital
BioCardia
BioE
BioEden
Biogenea-Cellgenea
Bioheart, Inc
Biologic Therapies
Biomatrica
BioMet Orthopedics
Biotec Services International
BioTime
BioTime Asia
Blackstone Medical
Bluebird Bio
BMJ (The British Medical Journal)
Boston Children's Hospital
BrainStorm Cell Therapeutics

Caladrius Biosciences
California Institute for Regenerative Medicine (CIRM)
Calimmune
Capricor
Cardio3
Caribou
Carolinas Cord Blood Bank (CCBB)
Casey Eye Institute
Cedars-Sinai Heart Institute
Cell (journal)
Cell Cure Neurosciences
Cell Therapy Catapult
CellCentric
Cellectis
Cellerant Therapeutics
Cellerix
CELLTREE
Cellular Biomedicine Group (CBMG)
Cellular Dynamics International
Center for International Blood and Marrow Transplant Research (CIBMTR)
Centers for Medicare & Medicaid Services
Cephalon
Cesca Therapeutics
Ceylad
Cha General Hospital
China Cord Blood Corporation
China Food and Drug Administration (CFDA)
Chinese Academy of Sciences
Chinese Ministry of Health
Chinese Ministry of Science and Technology
CJ CheilJedang
Clal Biotechnologies Industries
Cleveland Biolabs
Clinicaltrials.gov
ClinImmune Labs
Cochrane
Cognate BioServices
Committee for Medicinal Products for Human Use (CHMP)
Consortium of Multiple Sclerosis Centers
Cook General BioTechnology
Cord Blood America
Cord Blood Registry Systems
Cordlife Group
CRISPR Therapeutics
Cryo-Cell International
CryoCord
Cryonix CJSC
Cryo-Save
CXR Biosciences
Cytori Therapeutics

Data Safety Monitoring Board (DSMB)
Denali Ventures
Dendreon
Dong-A Pharmaceuticals Co
Drugs and Cell Therapies in Haematology (Journal)
Duke University School of Medicine
Elbit Imaging
Elbit Medical Technologies
Eli Lilly
Elsevier
EMA
EMA Committee for Orphan Medicinal Products
EpiStem
ESI Bio
European Court of Human Rights
European Court of Justice
European Group for Blood and Marrow Transplantation (EBMT)
European Haematology Association
EuroStemCell
Fate Therapeutics
FDS Pharma
Federal D.C. Court of Appeals
Fondazione Centro San Raffaele
Fondazione Telethon
Forbion Capital Partners
Forticell Bioscience
Gamida Cell
Gemabank
Gene Therapy Advisory Committee
Genetico
Genetrix Group
Geron
Gilead
GlobalStem
Globocan
GSK

Harvard Apparatus Regenerative Technology
Harvard Business School
Harvard Stem Cell Institute
Harvard University
Howard Hughes Medical Institute
Human Fertilisation and Embryology Authority (HFEA)
Human Stem Cells Institute
Human Tissue Authority
ImmunoCellular Therapeutics
Immunovative Therapies
Indian Department of Biotechnology
Insception Biosciences
Intellia Therapeutics
IntelliCell Biosciences
International Society for Stem Cell Research (ISSCR)
International Stem Cell Corporation (ISCO)
International Stemcell Services
IPS Academia Japan
Isar Medical Centre
Israel Healthcare Venture
Israel Stem Cell Society
Japan Institute of Biomedical Research.
Japan's Ministry of Economy, Trade and Industry (METI)
Japanese Health Ministry
Japanese Ministry of Labour and Welfare (MHLW)
Japanese Pharmaceuticals and Medical Devices Agency
JCR Pharmaceuticals
JingYuan Bio
Johnson & Johnson
Karolinska Institute
Korean Food and Drug Administration
Korean MFDS (Ministry of Food and Drug Safety)
Lifebank Cryogenics
LifebankUSA
LifeMap Sciences
LifeMap Solutions
LifeSouth Community Blood Centers Inc
Lonza

Massachusetts General Hospital
Maxcyte
Mayo Clinic
McMaster University
MedCell Bioscience
MEDIPOST
Medistem Panama
Medtronic
Mesoblast
Miltenyi Biotec
Musculoskeletal Transplant Foundation (MTF)
National Dental Pulp Laboratory
Nature (journal)
Nature Biotechnology (Journal)
NeoStem
Neuralstem
New England Journal of Medicine
New York Blood Center
New York Blood Center's Milstein National Cord Blood Program (NCBP)
New York Heart Association
NHS Blood and Transplant Authority
Northwestern University
Novartis
Novartis Research Foundation
NurOwn
Nuvasive
Ocata Therapeutics
OncoCyte
Opexa Therapeutics
Oregon Health and Science University
OrLife Bio
Orthofix
Osiris Therapeutics
Pahrump Valley Times
Pfizer
Pharmicell
Pharmsynthez
Plasticell
Pluristem
Polyphor
Prix Galien
Q Therapeutics
Queen Mary University of London
Quest Biomedical

ReCyte
Regenerative Sciences
Regenerex
Regeneron
Regeneus
Reliance Group
Reliance Life Sciences
ReNeuron
RepliCel Life Sciences
Reprobank
ReproCELL
RIKEN Center for Developmental Biology
Roche
Roslin Cellab
RTI Biologics
RTI Surgical
RUSNANO Corporation
RVC OJSC
SanBio
Sangamo BioSciences
Sanofi
Science (journal)
S-Evans Biosciences
Spinesmith Partners
SSM Cardinal Glennon Children's Medical Center
Stem Cell Bank
Stemcell Technologies
StemCells
StemCore
StemCyte
Stemedica Cell Technologies
StemGen
Stemina Biomarker Discovery
SynBio
TAP Biosystems (Sartorius Stedim Biotech
Tel Aviv University
Teva
The Committee for Advanced Therapies (CAT)
The European Commission
The Lancet
The London Project to Cure Blindness
The Marcus Foundation
The Zon Laboratory
Therapeutic Goods Administration
TiGenix
Tong Yuan Stem Cell
TrakCel
Translational Biosciences

U.S. Stem Cell, Inc
UCL Business PLC
UCL Institute of Ophthalmology
UCLA
UK Care Quality Commission
UK Department of Health
UK Department of Health and the Medical Research Council
UK Home Office
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
UK National Institute for Health Research
UK Regenerative Medicine Platform
uniQure
United Nation's Department of Economic and Social Affairs
University of California
University of Colorado Anschutz Medical Campus (AMC)
University of Colorado Cord Blood Bank
University of Kyoto
University of Massachusetts
University of Washington
University of Western Ontario
University of Wisconsin Alumni Research Foundation
US Congress
US District Court for the District of Columbia
US FDA
US National Cord Blood Program
US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institute of Health (NIH)
US National Marrow Donor Program
US National Marrow Donor Program (NMDP)
US Patent and Trademark Office
US Supreme Court
Valeant
Vericel Corporation
Vesta Therapeutics
ViaCord
ViaCyte
ViroMed
Vitro Biopharma
WA Optimum Health Care
WHO
Yale University

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com